GlassScriptPhysician profile
Irfan A Khan
NPI 1033186531
$10,627.49
in general payments reported to CMS, 2019-2025
51 companies · $1,954 in 2025
The $1,954 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,020 · 2020: $372 · 2021: $1,104 · 2022: $1,945 · 2023: $1,982 · 2024: $2,250 · 2025: $1,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,175 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,175.12 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,268.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,209.80 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Cequr Corporation | $894.73 | 2023-2025 | Cequr Simplicity |
| Corcept Therapeutics | $678.38 | 2019-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $510.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $504.52 | 2019-2023 | Farxiga |
| Abbvie INC. | $420.64 | 2019-2025 | |
| Insulet Corporation | $387.48 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $317.49 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Abbott Laboratories | $284.85 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $260.91 | 2020-2025 | Evenity, Prolia, Tepezza |
| Tandem Diabetes Care, INC. | $256.20 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $199.59 | 2022-2025 | |
| Antares Pharma, INC. | $186.53 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Amneal Pharmaceuticals LLC | $184.39 | 2019-2025 | Unithroid |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $157.16 | 2019-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $151.14 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.32 | 2021-2025 | Jardiance |
| Radius Health, INC. | $137.42 | 2019-2024 | Tymlos |
| Medtronic, INC. | $136.75 | 2021-2024 | Minimed 780g |
| Amphastar Pharmaceuticals, INC. | $121.99 | 2025 | |
| Madrigal Pharmaceuticals | $106.91 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $95.40 | 2023-2024 | Strensiq |
| Ascensia Diabetes Care US INC. | $79.85 | 2022-2023 | |
| Recordati_rare_diseases_inc. | $75.11 | 2022-2025 | Isturisa, Signifor Lar |
| Merck Sharp & Dohme LLC | $65.70 | 2020-2021 | |
| Astellas Pharma US INC | $62.49 | 2023-2025 | Veozah, Myrbetriq |
| Kyowa Kirin, INC. | $62.05 | 2022-2023 | Crysvita |
| Amryt Pharma Holdings LTD | $59.10 | 2021-2023 | Mycapssa |
| Janssen Pharmaceuticals, INC | $45.65 | 2019-2020 | |
| Horizon Therapeutics Plc | $44.87 | 2019-2023 | Tepezza |
| Pfizer INC. | $36.91 | 2019-2022 | |
| Acella Pharmaceuticals, LLC | $36.30 | 2025 | NP Thyroid 60 |
| Tolmar, INC. | $33.68 | 2023-2024 | |
| Becton, Dickinson and Company | $31.25 | 2022 | |
| Boston Scientific Corporation | $28.04 | 2025 | Wavewriter Alpha Prime 16 |
| Medtronic Minimed, INC. | $27.87 | 2019 | |
| Acerus Pharmaceuticals Corporation | $27.70 | 2021 | |
| Embecta Corp. | $27.43 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Beta Bionics, INC. | $26.83 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Regeneron Healthcare Solutions, INC. | $26.71 | 2025 | Eylea Hd |
| Zealand Pharma US, INC. | $26.62 | 2021 | |
| Shire North American Group INC | $26.48 | 2019 | |
| Baxter Healthcare | $25.05 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Chiesi USA, INC. | $22.22 | 2024 | Mycapssa |
| Eusa Pharma (US) LLC | $21.20 | 2022 | |
| Nevro Corp. | $21.14 | 2022 | |
| Neurocrine Biosciences, INC. | $20.59 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.48 | 2020 | |
| Halozyme INC | $17.35 | 2023 | |
| Clarus Therapeutics INC. | $14.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irfan Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.